



Clarification Statement

Perth, Australia & Malta – 10 January 2018 – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), wishes to provide further clarification on the Company’s announcement released on 8 January 2018 “[Clinical Trial – Data Collection Complete](#)”.

When the Carrick Institute advised that the US Clinical Trial had reached the milestone of having completed data collection, the Company was also notified that the final results of the study would not be made available to Neurotech or the public until the investigation has been published, as stated in the announcement of 8 January 2018.

At Neurotech’s annual general meeting (“AGM”) on 23 November 2017, we provided an investor presentation (available at the following [link](#)) which noted the Company’s expectations of when the results of the US Clinical Trial would be available, when the submission to the US FDA could be made and the publication of these results in peer-reviewed publications. The Company’s expectation at the time of the AGM was that these events would occur in that order.

Based on our understanding of the nature of these trials, the Company’s expectation now is that the results will become public within a few months of data collection being completed, which will be concurrent with publication of these results and submission to the US FDA.

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

For more information please contact:

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com